New Hope for Solid Tumors! DS-8201 Achieves Over 22 Months of Sustained Relief and Receives Two Breakthrough Therapy Designations
Since the emergence of several new drugs for the treatment of solid tumors, such as larotrectinib and entrectinib, the concept of “broad-spectrum anti-cancer drugs” has officially entered public awareness. Years later, more and more broad-spectrum anti-cancer drugs have moved from the laboratory to clinical settings, officially ushering in this precise yet “broad-spectrum” era of cancer … Read more